Developing a new class of engineered live bacterial therapeutics to treat human diseases

por Charbonneau, Mark R., Isabella, Vincent M., Li, Ning, Kurtz, Caroline B.
Publicado 2020

Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria

por Charbonneau, Mark R., Denney, William S., Horvath, Nicholas G., Cantarella, Pasquale, Castillo, Mary J., Puurunen, Marja K., Brennan, Aoife M.
Publicado 2021

Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip

por Nelson, M. Tyler, Charbonneau, Mark R., Coia, Heidi G., Castillo, Mary J., Holt, Corey, Greenwood, Eric S., Robinson, Peter J., Merrill, Elaine A., Lubkowicz, David, Mauzy, Camilla A.
Publicado 2021

An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria

por Lubkowicz, David, Horvath, Nicholas G, James, Michael J, Cantarella, Pasquale, Renaud, Lauren, Bergeron, Christopher G, Shmueli, Ron B, Anderson, Cami, Gao, Jian‐Rong, Kurtz, Caroline B, Perreault, Mylene, Charbonneau, Mark R, Isabella, Vincent M, Hava, David L
Publicado 2022